구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Repatha (evolocumab) |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | PCSK9 |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies |
Positioning Development positioning | PCSK9 mAb vs inclisiran siRNA (Leqvio) dosing convenience trade-off |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. |
PK/PD Half-life | 17 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Hamster |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | No major organ toxicity; injection-site reactions |
Toxicology CRS | N/A |
Clinical Safety signal | No major organ toxicity; injection-site reactions |
Clinical Selected reported efficacy | 67% |
Clinical Result source | ClinicalTrials.gov NCT05144529 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05144529 |
Preclinical Animal (cat.) | Mouse, In vitro |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Repatha (evolocumab) |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | PCSK9 |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies |
Positioning Development positioning | PCSK9 mAb vs inclisiran siRNA (Leqvio) dosing convenience trade-off |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. |
PK/PD Half-life | 17 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Hamster |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | No major organ toxicity; injection-site reactions |
Toxicology CRS | N/A |
Clinical Safety signal | No major organ toxicity; injection-site reactions |
Clinical Selected reported efficacy | 67% |
Clinical Result source | ClinicalTrials.gov NCT05144529 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05144529 |
Preclinical Animal (cat.) | Mouse, In vitro |
추천 비교
추천 비교